Startseite
Podcasts
60-Second Science Podcast
GLP-1 drugs are entering a new chapter

GLP-1 drugs are entering a new chapter

60-Second Science vor 6 Monaten

“Imitation” drugs, unexpected benefits, serious pitfalls—here’s what comes next as GLP-1 medications continue to rise in popularity

0:00

15:39

In this episode of Science Quickly, Scientific American’s associate
health editor Lauren Young joins host Kendra Pierre-Louis to talk
about how the story of GLP‑1 drugs such as Ozempic, Wegovy and
Mounjaro is evolving. We trace GLP-1s’ origins as type 2 diabetes
treatments, their rise as blockbuster weight‑loss medications and
the ensuing complications—including the expanding market for
compounded drugs. And we look at how the landscape has only grown
more complex as researchers explore surprising potential uses for
GLP‑1s, from addiction treatment to cardiovascular benefits, even
as new concerns emerge about long‑term effects. Recommended
Reading: Compound weight-loss drugs are everywhere. The FDA is
cracking down People who took GLP-1 drugs had lower risk of all
kinds of drug and alcohol addiction E-mail us at
sciencequickly@sciam.com if you have any questions, comments or
ideas for stories we should cover! Discover something new everyday:
subscribe to Scientific American and sign up for Today in Science,
our daily newsletter. Science Quickly is produced by Kendra
Pierre-Louis, Fonda Mwangi, Sushmita Pathak and Jeff DelViscio.
This episode was edited by Alex Sugiura, with fact-checking by
Shayna Posses and Aaron Shattuck. Our theme music was composed by
Dominic Smith. Learn more about your ad choices. Visit
megaphone.fm/adchoices